and transfected with NG2-shRNA (stable), miR129-2 (transient) or treated with 5-Azacytidine. 
Supplementary Figure 4: NG2 expressing cells lack terminal differentiation. Primary
neurospheres from PDGF mouse tumor were fixed and immunostained using primary antibodies for NG2, GFAP, and Olig2 for flow cytometry analysis. Mouse primary cells coexpress NG2 and Olig2 at 55.6%. Similarly, 54% of mouse neurospheres co-express both GFAP and NG2. Co-expression of astrocyte (GFAP) and oligodendrocyte marker (Olig2) is 55.6%.
The robust co-expression of any two antibodies indicates the lesser degree of commitment of mouse tumor cells. 
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